The FDA approved lerodalcibep (Lerochol) injections for the treatment of elevated LDL cholesterol in adults, maker LIB Therapeutics announced. A third-generation PCSK9 inhibitor, lerodalcibep is ...
Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...
WASHINGTON, DC — In order to be cost-effective for patients, providers, and payers, the new proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors would need to cost around $2400 per year, a mark ...
Adding a PCSK9 inhibitor to maximally tolerated statins after a coronary or peripheral artery revascularization can help patients achieve LDL cholesterol goals better than standard care, data from the ...
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, lipid-lowering drugs, were associated with a 22% lower risk for nonmelanoma skin cancer (NMSC) in patients with atherosclerotic ...
Enlicitide, an oral PCSK9 inhibitor, reduced LDL-C by nearly 60% in adults with or at risk for ASCVD. The medication offers a daily oral alternative to injectable PCSK9 inhibitors, potentially ...
Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma unveiled a pair of phase 3 wins for enlicitide decanoate in patients with high ...
Panelists discuss how PCSK9 inhibitors remain underused due to access, cost, and adherence barriers. Panelists discuss how PCSK9 inhibitors remain underutilized despite their strong efficacy and ...
The highest dose of AstraZeneca’s small molecule halved levels of a type of “bad” cholesterol after 12 weeks, hitting the goal of a phase 2 trial in patients with a lipid disorder. The candidate in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results